Innate Pharma schedules November 10 Stifel fireside chat

The Stifel fireside chat will have a live webcast link on Innate Pharma’s investor Events page, followed by a replay after the event.

Rhea-AI Filing Summary

Innate Pharma SA announced that members of its executive team will participate in the Stifel Healthcare Conference in New York, November 10–12, 2026, and the Jefferies Global Healthcare Conference in London, November 16–19, 2026. A Stifel fireside chat is scheduled for November 10, 2026, at 2:00 p.m. ET / 8:00 p.m. CET; its live webcast link will be available on the company’s investor Events page, and a replay will be available following the event. Innate describes its proprietary pipeline as centered on antibody-drug conjugates, led by IPH4502, and identifies lacutamab with Sobi and monalizumab with AstraZeneca as partnered assets.

Key Figures

Stifel conference dates: November 10–12, 2026 Stifel fireside chat: November 10, 2026, 2:00 p.m. ET / 8:00 p.m. CET Jefferies conference dates: November 16–19, 2026

3 metrics

Stifel conference dates November 10–12, 2026 New York, United States

Stifel fireside chat November 10, 2026, 2:00 p.m. ET / 8:00 p.m. CET Scheduled presentation

Jefferies conference dates November 16–19, 2026 London, United Kingdom

Key Terms

antibody-drug conjugates (ADCs), Nectin-4 ADC, non-small cell lung cancer (NSCLC)

3 terms

antibody-drug conjugates (ADCs) technical

"proprietary pipeline is centered on antibody-drug conjugates (ADCs)"

Antibody-drug conjugates (ADCs) are advanced medicines that combine a targeted antibody with a powerful drug, acting like a guided missile to deliver treatment directly to cancer cells while sparing healthy tissue. This precision approach can improve effectiveness and reduce side effects, making ADCs a promising area of biotech innovation. For investors, advancements in ADC technology can signal potential growth opportunities in the pharmaceutical and healthcare sectors.

Nectin-4 ADC medical

"a differentiated Nectin-4 ADC in clinical development for solid tumors"

non-small cell lung cancer (NSCLC) medical

"monalizumab, developed with AstraZeneca for non-small cell lung cancer (NSCLC)"

A common group of lung cancers that arise from the lungs’ cell lining and grow in ways different from the faster-spreading “small cell” form; think of it as several related varieties of the same illness rather than one single disease. It matters to investors because diagnosis rates, new drugs, diagnostic tests, and clinical trial results for these cancers can drive large, sustained revenue opportunities and regulatory decisions that materially affect healthcare and biotech company valuations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/21/2026 - 06:08 AM EDT Accepted by SEC EDGAR 10/21/2026 - 06:08 AM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

Date of report: Tuesday October 21, 2026

Commission File Number: 001-39084

Innate Pharma S.A.

(Translation of registrant's name into English)

Innate Pharma S.A.

117 Avenue de Luminy—BP 30191

13009 Marseille, France

+ 33 (0) 4 30 30 30

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ]    Form 40-F [ ]

EXHIBIT INDEX

Exhibit Description

99.1    Press Release dated October 21, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

INNATE PHARMA S.A.

Date: October 21, 2026 By: /s/ JONATHAN DICKINSON Name: Jonathan Dickinson

Title:    Chief Executive officer

EXHIBIT 99.1

INNATE PHARMA TO PARTICIPATE IN THE STIFEL HEALTHCARE CONFERENCE AND JEFFERIES GLOBAL HEALTHCARE CONFERENCE

Marseille, France, October 21, 2026

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that members of its executive team will participate in the following investor conferences:

Stifel Healthcare Conference

•Dates: November 10–12, 2026

•Location: New York, United States

Fireside chat:

•Date: November 10, 2026

•Time: 2:00 p.m. ET / 8:00 p.m. CET

•To enter the live webcast, please click here

The link to access the live webcast of the presentation will be available on the Events page of the Investors section of Innate Pharma’s website. A replay of the presentation will be available following the event.

Jefferies Global Healthcare Conference

•Dates: November 16-19, 2026

•Location: London, United Kingdom

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise in antibody engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics.

Innate Pharma is advancing a portfolio of differentiated potential first-and/or best-in-class assets, focused on areas of high unmet medical need. Its proprietary pipeline is centered on antibody-drug conjugates (ADCs), led by IPH4502, a differentiated Nectin-4 ADC in clinical development for solid tumors, and supported by a preclinical portfolio of next-generation ADC candidates. In parallel, Innate is advancing two partnered late-stage assets: lacutamab, developed with Sobi for T-cell lymphomas, and monalizumab, developed with AstraZeneca for non-small cell lung cancer (NSCLC).

Innate Pharma has established collaborations with leading biopharmaceutical companies, including Sobi, Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology.

Headquartered in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.

Information about Innate Pharma shares

ISIN code: FR0010331421

Ticker code: Euronext Paris: IPH | Nasdaq: IPHA

LEI: 9695002Y8420ZB8HJE29

Disclaimer on forward-looking information and risk factors

For a discussion of risks and uncertainties, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company’s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

Contacts

Stéphanie Cornen

VP, Investor Relations & Corporate Communications

stephanie.cornen@innate-pharma.fr

Investor Relations

investors@innate-pharma.fr

Media 

communication@innate-pharma.fr 

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EX-99.1 11.9 KB